Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS intra-articular placebo-controlled study in primary knee osteoarthritis
2025-524668-39-00Phase 2Authorised
- Sponsor
- Enlivex Therapeutics
- Start
- May 2026
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing Allocetra-OTS with Matching placebo (2 arms). Primary endpoints: Change from baseline in WOMAC Pain score at 3 months, Change from baseline in WOMAC Function score at 3 months and 1 more. Planned start May 2026; status: authorised.
02
Drugs
Allocetra
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2025-524668-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524668-39-00.